<a href="https://laohu8.com/S/TSBX">Turnstone Biologics Corp.</a> Announces Delisting from Nasdaq Following Merger Completion
Turnstone Biologics Corp. has announced a regulatory action related to its merger with XOMA Royalty Corporation. Following the completion of the merger, Turnstone has notified the Nasdaq Capital Market LLC of the merger's consummation and requested the suspension of trading of its shares, effective before the opening of trading on August 11, 2025. Additionally, Turnstone has filed a Notification of Removal from Listing and/or Registration on Form 25 with the SEC to effect the delisting of all its shares from Nasdaq. The company also plans to file a Certification and Notice of Termination of Registration on Form 15 to terminate the registration of its shares under Section 12(g) of the Securities Exchange Act of 1934 and suspend reporting obligations under Sections 13 and 15(d) of the Exchange Act.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turnstone Biologics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-177597), on August 11, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。